Hagens Berman probes Embecta after lawsuit over insulin pen needle disclosures

The law firm points to a May 5, 2026 guidance cut, dividend reduction and a 57.8% one-day stock drop tied to alleged misstatements about Embecta’s core business.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.